The Retinal Disorder Drugs Clinical Pipeline 2021​


​Release Date: Q3' 2021
Number of Candidates: 90

Synopsis: Retinal disorders such as AMD (Age-Related Macular Degeneration) and diabetic eye disease can significantly impair vision by damaging the tissue layer at the back of the eye responsible for light detection. In severe cases, certain retinal disorders can even result in permanent blindness, making timely treatment critical.

Retinal disorders are typically treated with drugs, laser treatment or surgery. Largely dominated by anti-VEGF (Vascular Endothelial Growth Factor) therapies, drugs remain the preferred approach to treat most cases of retinal disorders. Retinal disorder drug sales are expected to account for more than $20 Billion by the end of 2021. The R&D pipeline for retinal disorder drugs is primarily focused on long-acting VEGF inhibition, dual inhibition of Ang-2 (Angiopoietin-2)/VEGF, TKIs (Tyrosine Kinase Inhibitors), anti-integrin therapy, neuroprotective agents, Tie-2 activation, complement inhibition, and gene and cell therapies.

With several promising candidates in the pipeline, drug developers are closer to making the first breakthrough in the treatment for dry AMD, approval is expected between 2022 and 2025. The regulatory approval of next-generation anti-VEGF therapies will pave the way for patient-friendly treatment regimens – with less frequent dosing than currently approved therapies for wet AMD.
​
Approval of Spark Therapeutics’ Luxturna, a novel gene therapy drug, has paved the way for transformative therapies in the retinal space. Several gene therapies are presently in late-stage clinical development for conditions such as LHON (Leber Hereditary Optic Neuropathy), Stargardt disease and retinitis pigmentosa – as well as AMD and diabetic retinopathy.
For a Sample and Inquiries please contact [email protected]

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate (Name)
  • Drug Developer(s)
  • Phase
    • Phase I
    • Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Clinical
    • Pre-Registration
  • Therapeutic Category  ​
    • AMD
    • Diabetic Eye Disease
    • Retinitis Pigmentosa
    • Multiple 
    • ​Others
  • Type
    • Biosimilar
    • Gene & Stem Cell Therapy
    • New Delivery Technology
    • ​New Molecular Entity
    • New indication​
​